Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arata Azuma

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
Respiratory Investigation|November 23, 2020
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trialArata Azuma, Lorinda Chung, Digambar Behera, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialJustin M Oldham, Arata Azuma, Michael Kreuter, et al.
Diagnostic Microbiology and Infectious Disease|February 18, 2010
Sequential changes of Legionella antigens and bacterial load in the lungs and urines of a mouse model of pneumoniaYu Chen, Kazuhiro Tateda, Kazue Fujita, et al.
International Journal of Clinical Oncology|July 29, 2019
Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II studyAya Fukuizumi, Yuji Minegishi, Miwako Omori, et al.
Experimental Cell Research|December 11, 2020
Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axisMinoru Inomata, Koichiro Kamio, Arata Azuma, et al.
Respiratory Investigation|April 15, 2019
Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposalKentaro Watanabe, Hiroshi Ishii, Fumiaki Kiyomi, et al.
Internal Medicine (Tokyo, Japan)|August 16, 2008
Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex diseaseMasao Okumura, Kazuro Iwai, Hideo Ogata, et al.
Respiratory Research|December 1, 2020
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in JapanKimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|March 6, 2009
[A case of suspected idiopathic pulmonary upper lobe fibrosis (Amitani disease) with acute exacerbation]Takahito Nei, Masashi Kawamoto, Etsuko Satoh, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
Respiratory Investigation|November 23, 2020
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trialArata Azuma, Lorinda Chung, Digambar Behera, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialJustin M Oldham, Arata Azuma, Michael Kreuter, et al.
Diagnostic Microbiology and Infectious Disease|February 18, 2010
Sequential changes of Legionella antigens and bacterial load in the lungs and urines of a mouse model of pneumoniaYu Chen, Kazuhiro Tateda, Kazue Fujita, et al.
International Journal of Clinical Oncology|July 29, 2019
Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II studyAya Fukuizumi, Yuji Minegishi, Miwako Omori, et al.
Experimental Cell Research|December 11, 2020
Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axisMinoru Inomata, Koichiro Kamio, Arata Azuma, et al.
Respiratory Investigation|April 15, 2019
Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposalKentaro Watanabe, Hiroshi Ishii, Fumiaki Kiyomi, et al.
Internal Medicine (Tokyo, Japan)|August 16, 2008
Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex diseaseMasao Okumura, Kazuro Iwai, Hideo Ogata, et al.
Respiratory Research|December 1, 2020
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in JapanKimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|March 6, 2009
[A case of suspected idiopathic pulmonary upper lobe fibrosis (Amitani disease) with acute exacerbation]Takahito Nei, Masashi Kawamoto, Etsuko Satoh, et al.
Pageof 23